Shots:
- FDA has approved Libre Duo 10 Day, a dual glucose-ketone sensing biowearable, to provide real-time glucose monitoring while continuously detecting rising ketones for diabetic ketoacidosis (DKA) emergency, with launch expected later this year
- Libre Duo 10 Day met FDA standards for both integrated continuous glucose monitoring (iCGM) & the new integrated continuous glucose & ketone monitoring (iCGK) standard, offering ~10 days of wear & is intended for people with diabetes aged 2 yrs. & older
- Abbott is partnering with leading pump makers to integrate Libre Duo 10 Day with automated insulin delivery systems, incl. Beta Bionics’ iLet & Sequel Med Tech’s twiist by year-end, Insulet & Tandem in 2027, plus an exclusive Abbott-MiniMed integration expected in 2027
Ref: PRnewswire | Image: Abbott | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
